Login / Signup

Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2- breast cancer.

Mitch DowsettLucy Suzanne KilburnMothaffar F RimawiC Kent OsborneKatherine Pogue-GeileYuan LiuSamuel A JacobsMelanie FinniganShannon PuhallaAndrew DodsonVera MartinsMaggie Chon U CheangSophie PerryChris HolcombeNick TurnerClaire SwiftJudith M BlissStephen Johnstonnull null
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
High CCNE1 levels were confirmed as a biomarker of resistance to letrozole+palbociclib. Ki67 recovery within 3-9 days of discontinuing palbociclib indicates incomplete suppression of proliferation during the "off" week of its schedule.
Keyphrases